PBYI (STOCKS)
PUMA BIOTECHNOLOGY INC
$7.070000
-0.260000 (-3.55%)
Prev close: $7.330000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Alan H. Auerbach
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $360.88M
- Employees
- 172
- P/E (TTM)
- 15.35
- P/B (TTM)
- 2.90
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
0
Strong Buy
0
Buy
3
Hold
1
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Mar 2026 (Q1)
|
$-0.07 | $-0.13 | +0.0626 | +47.21% |
|
Dec 2025 (Q4)
|
$0.26 | $0.23 | +0.0285 | +12.31% |
|
Sep 2025 (Q3)
|
$0.17 | $0.05 | +0.1241 | +270.37% |
|
Jun 2025 (Q2)
|
$0.12 | $0.10 | +0.0153 | +14.61% |
Financial Statements
| Revenues | $227.18M |
| Benefits Costs and Expenses | $198.09M |
| Cost Of Revenue | $58.03M |
| Costs And Expenses | $197.69M |
| Gross Profit | $169.15M |
| Nonoperating Income/Loss | -$399.00K |
| Operating Expenses | $139.67M |
| Selling, General, and Administrative Expenses | $71.67M |
| Depreciation and Amortization | $10.73M |
| Other Operating Expenses | $62.76M |
| Operating Income/Loss | $29.49M |
| Income/Loss From Continuing Operations After Tax | $24.38M |
| Income/Loss From Continuing Operations Before Tax | $29.09M |
| Income Tax Expense/Benefit | $4.70M |
| Income Tax Expense/Benefit, Current | $1.46M |
| Net Income/Loss | $24.38M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $24.38M |
| Net Income/Loss Available To Common Stockholders, Basic | $24.38M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $0.50 |
| Diluted Earnings Per Share | $0.48 |
| Basic Average Shares | 151,015,107 |
| Diluted Average Shares | 152,238,457 |
| Assets | $192.70M |
| Current Assets | $142.26M |
| Cash | $91.66M |
| Inventory | $8.69M |
| Prepaid Expenses | $3.41M |
| Other Current Assets | $38.50M |
| Noncurrent Assets | $50.44M |
| Fixed Assets | $124.00K |
| Other Non-current Assets | $50.32M |
| Liabilities | $64.28M |
| Current Liabilities | $59.74M |
| Accounts Payable | $8.17M |
| Wages | $5.36M |
| Other Current Liabilities | $46.21M |
| Noncurrent Liabilities | $4.55M |
| Long-term Debt | $11.34M |
| Equity | $128.42M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $128.42M |
| Liabilities And Equity | $192.70M |
| Net Cash Flow From Operating Activities | $53.61M |
| Net Cash Flow From Operating Activities, Continuing | $53.61M |
| Net Cash Flow From Investing Activities | -$35.25M |
| Net Cash Flow From Investing Activities, Continuing | -$35.25M |
| Net Cash Flow From Financing Activities | -$45.20M |
| Net Cash Flow From Financing Activities, Continuing | -$45.20M |
| Net Cash Flow | -$26.84M |
| Net Cash Flow, Continuing | -$26.84M |
| Comprehensive Income/Loss | $24.36M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $24.36M |
| Other Comprehensive Income/Loss | $24.36M |